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eterozygous activating mutations in the KCNJ11 gene are a common cause of permanent neonatal diabetes (PNDM) (1, 2) . In contrast to the autoimmune type 1 diabetes, patients with KCNJ11 mutations do not have serological markers of autoimmune ␤-cell destruction at disease onset (1, (3) (4) (5) . In such patients, hyperglycemia does not result from insulin-secreting cell destruction but rather from impaired insulin secretion. In addition, the majority of cases can be corrected with sulfonylurea therapy (2, 6) . Here, we report that carriers of the KCNJ11 mutation that are immunonegative at onset may show presence of islet antibodies in the further course of the disease. Nonparametric statistics using the Mann-Whitney U test were applied to assess the differences between groups.
RESEARCH DESIGN AND METHODS
RESULTS -Of 11 patients tested for the presence of islet antibodies, 5 were positive (Table 1) . Among patients with Ͼ10 years' duration of neonatal diabetes, more than one-half showed the presence of at least one islet antibody. The relationship between disease duration and the occurrence of autoantibodies is shown in supplemental Fig. 2 . Of five sera collected from the R201H mutation carriers, two (in subjects aged 13 and 50 years) were positive for islet antibodies. Moreover, two subjects with phenotypically more severe mutation, V59M, were negative for tested autoantibodies (Table 1) . Thus, it is likely that the type of mutation is not related to the presence of autoantibodies. Despite detectable markers of isletspecific autoimmune process, all five patients responded well to sulfonylurea treatment, which indicates that a sufficient number of ␤-cells remained to maintain glucose homeostasis.
CONCLUSIONS -Humoral markers of autoimmune type 1 diabetes are absent at onset of PNDM. This finding is consistent with all published studies on neonatal diabetes, due to mutation in the KCNJ11 gene (1, (3) (4) (5) . In our patients' records, antibody measurement at disease onset were available for only five subjects, and, systematically, all patients were negative for ␤-cell-specific autoantibodies.
Our results demonstrate that immunonegative-at-onset carriers of the KCNJ11 mutation may show seroconversion with long duration of the disease. It is known that apoptosis in ␤-cells can be elicited by various stimuli, including the perturbation of the metabolic and signal pathways (9 -12).
Gain-of-function mutations in Kir6.2 severely disturb metabolism of pancreatic ␤-cells, possibly promoting increased cell turnover. Recurrent exposure of tissuespecific antigens could lead to primary sensitization of immune cells. It appears that in this subgroup of patients, an autoimmune process may occur as a secondary effect to severe cell dysfunction, which results from KCNJ11 mutation.
All studies published to date that tested behavior of cells in the presence of mutated Kir6.2 focused on short-term effects. For instance, Lin et al. (13) did not observe a proapoptotic effect of mutated Kir6.2 in the insulin-secreting cell line INS-1 during their up to 1 week of experiments. Among patients with the KCNJ11 mutation, seroconversion occurs after at least a 10-year duration of PNDM. Therefore, it would be interesting to check the long-term effect of mutated Kir6.2 on the survival of insulin-secreting cells.
It has been reported that not all patients with PNDM caused by mutated Kir6.2 can transfer from insulin to sulfonylurea therapy (2) . In some cases, it can be explained by the severity of mutation, as was demonstrated by in vitro studies (14). Interestingly, two diabetic mothers of two children also affected who responded well to sulfonylureas were resistant to this therapy. This observation shows that mutation type is not the only limiting factor in successful transfer to sulfonylureas and that diabetes duration may have an additional impact. Presence of islet antibodies proves that autoimmune response can be triggered in patients with mutated Kir6.2 protein.
Ongoing processes may be responsible for the destruction of pancreatic islets, which in turn preclude treatment with sulfonylureas. Conversely, it is still speculative whether the autoimmune process could constitute an explanation for an observed lack of response to sulfonylurea therapy in some individuals with a long duration of PNDM.
Moreover, our finding is of clinical importance regarding type 1 diabetes diagnosis qualification versus type 2 or gestational diabetes. The presence of islet antibodies in patients with long duration of neonatal diabetes exemplifies that immune reaction against ␤-cells is not exclusively observed in type 1 diabetes. Therefore, diabetes diagnosis at age Ͻ6 months and lack of antibodies at the onset (but not in the later course of the disease) should constitute inclusion criteria for genetic evaluation of PNDM. 
